ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.417,55
0,62%
S&P 500
5.459,10
1,11%
Dow Jones
40.589,34
1,64%
Euro vs US Dollar
1,08715
-0,01%
Bitcoin
68.402,67
0,72%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ReShape Lifesciences Inc (RSLS)

  7. ReShape Lifesciences Inc (RSLS) News

RSLS

ReShape Lifesciences (RSLS)

ReShape Lifesciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RSLS
DatumZeitQuelleÜberschriftSymbolFirma
09/07/202418h13GlobeNewswire Inc.Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”NASDAQ:RSLSReShape Lifesciences Inc
09/07/202415h22Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:RSLSReShape Lifesciences Inc
09/07/202415h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
09/07/202414h31GlobeNewswire Inc.ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad MedisysNASDAQ:RSLSReShape Lifesciences Inc
20/05/202423h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
15/05/202422h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RSLSReShape Lifesciences Inc
15/05/202422h05GlobeNewswire Inc.ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate UpdateNASDAQ:RSLSReShape Lifesciences Inc
14/05/202414h31GlobeNewswire Inc.ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateNASDAQ:RSLSReShape Lifesciences Inc
01/04/202422h05GlobeNewswire Inc.ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateNASDAQ:RSLSReShape Lifesciences Inc
28/03/202413h31GlobeNewswire Inc.ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon SystemNASDAQ:RSLSReShape Lifesciences Inc
04/03/202414h31GlobeNewswire Inc.ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEXNASDAQ:RSLSReShape Lifesciences Inc
26/02/202422h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
22/02/202414h31GlobeNewswire Inc.ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEXNASDAQ:RSLSReShape Lifesciences Inc
24/01/202414h31GlobeNewswire Inc.ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEXNASDAQ:RSLSReShape Lifesciences Inc
18/01/202422h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
17/01/202400h11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RSLSReShape Lifesciences Inc
05/01/202422h14Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RSLSReShape Lifesciences Inc
20/12/202314h31GlobeNewswire Inc.ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership AlternativesNASDAQ:RSLSReShape Lifesciences Inc
12/12/202322h05GlobeNewswire Inc.ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEXNASDAQ:RSLSReShape Lifesciences Inc
29/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
21/11/202314h06GlobeNewswire Inc.ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross ProceedsNASDAQ:RSLSReShape Lifesciences Inc
08/11/202322h05GlobeNewswire Inc.ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction PlanNASDAQ:RSLSReShape Lifesciences Inc
06/11/202314h31GlobeNewswire Inc.ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate UpdateNASDAQ:RSLSReShape Lifesciences Inc
13/10/202322h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
05/10/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
03/10/202315h23Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:RSLSReShape Lifesciences Inc
29/09/202318h30GlobeNewswire Inc.ReShape Lifesciences® Announces Pricing of $3.0 Million Public OfferingNASDAQ:RSLSReShape Lifesciences Inc
27/09/202323h30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RSLSReShape Lifesciences Inc
22/09/202322h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RSLSReShape Lifesciences Inc
22/09/202314h31GlobeNewswire Inc.ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVINASDAQ:RSLSReShape Lifesciences Inc
 Showing the most relevant articles for your search:NASDAQ:RSLS

Kürzlich von Ihnen besucht

BIT
F38408
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten